News - Generics
MAYNE PHARMA GROUP LTD : CEO's Address to Shareholders (PDF)
12 November 2012
This was recently exemplified by Mayne Pharma entering into a strategic licensing and distribution agreement with Intas Pharmaceuticals for a range of injectable generic products for the Australian market. Intas is one of India's leading pharma ...
Click on the link to read the full article at 4-traders (This link will open in a new window)Not Enough Cancer Drugs, Too Many Price Controls
11 November 2012
Almost all drug shortages have come about after their price has plummeted, and the problem is compounded by the fact that many generics have few suppliers. For example in 2010, 90% of all generic injectable oncology drugs were produced by three or ...
Click on the link to read the full article at Wall Street Journal (This link will open in a new window)Momenta's struggles show glimpse of new generic business
9 November 2012
To look at the recent past of Momenta Pharmaceuticals Inc. is to get a glimpse of what the future of the generic drug market will look like. The trend away from small-molecule oral drugs toward complex, large-molecule injectable ones will make it ...
Click on the link to read the full article at Mass High Tech (This link will open in a new window)Mylan: Profit From The Generics Boom With This Pharma
8 November 2012
Mylan (MYL) has proven that the patent cliff is an opportunity rather than a crackup for savvy drug makers. The generic drug specialist saw its revenue jump by 10% to $1.5 billion in the third quarter. The profit increase was driven largely by ...
Click on the link to read the full article at Seeking Alpha (This link will open in a new window)The case for generic drug tendering
8 November 2012
Generic drug companies often present themselves as a modern-day Robin Hood: taking from brand name drug companies, and passing the spoils on to Canadians. Public debate is brewing, however, over how to split the loot. Recently, the Canadian Generic ...
Click on the link to read the full article at Montreal Gazette (This link will open in a new window)OxyContin patent expiry poses tough choice for Ottawa
8 November 2012
25 to decide whether to allow drug companies to make a generic version of the painkiller OxyContin. The patent on the brand name version of that drug expires on that date and generic drug companies have already signalled an interest in making the ...
Click on the link to read the full article at CBC.ca (This link will open in a new window)Desi generic companies may get Obamacare booster shot
8 November 2012
MUMBAI: Domestic generic companies are expected to get a booster shot from US President Barack Obama's re-election which cements healthcare reforms in that country leading to more generic prescriptions, and hence a bigger market for generic drugs.
Click on the link to read the full article at Times of India (This link will open in a new window)Spectrum's Quarter Gets No Respect
7 November 2012
One of the keys to Spectrum's success is Fusilev. However, some have worried that generic rivals could chip away at sales for the drug. Were there any hints that those worries could be well-founded? Fusilev's numbers for the quarter answer that question.
Click on the link to read the full article at Motley Fool (This link will open in a new window)Why Teva Pharmaceutical Is An Attractive Buying Opportunity
7 November 2012
TEVA is an international pharmaceutical company headquartered in Petah Tikva, Israel. It specializes in generic and proprietary pharmaceuticals and active ingredients. It is the largest generic drug manufacturer and one of the 15 largest pharmaceutical ...
Click on the link to read the full article at NASDAQ (This link will open in a new window)The case for generic drug tendering
6 November 2012
Generic drug companies often present themselves as a modern-day Robin Hood: taking from brand name drug companies, and passing the spoils on to Canadians. Public debate is brewing, however, over how to split the loot. Recently, the Canadian Generic ...
Click on the link to read the full article at Vancouver Sun (This link will open in a new window)
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
